Surrozen opened lower at $29.32, compared with its previous close of $29.46. In the last trading session, the stock traded between $27.95 and $29.51. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Surrozen is now worth
$ 26.70
resulting in a loss of
$ 73.30 (73.30%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.42 (-4.82%)
Day High
$29.51
Day Low
$27.95
Day Open
$29.32
Prev Close
$29.46
Volume
63,215
1W Return
8.56%
1M Return
-12.13%
3M Return
46.42%
6M Return
-11.15%
1Y Return
106.33%
Fundamentals
Market Cap ($ Mn)
330
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-292.65%
EPS (TTM)
$2.73
Investment Returns
1 Week
8.56%
1 Month
-12.13%
3 Months
46.42%
6 Months
-11.15%
9 Months
26.99%
Financials
Quarterly
All values in $ Mn
0.7
Dec 24
1.0
Mar 25
1.0
Jun 25
1.0
Sep 25
0.5
Dec 25
5.0
Jun 26
Updates
21Oct
Surrozen closes $95.1M final tranche of private placement
Closed second and final tranche of March 2025 private placement for $95.1 million gross proceeds. Milestone triggered by FDA clearance of IND application for SZN-8141 on October 2, 2026. Cash runway extended into 2029 to fund DUET Phase 1b/2a study and SZN-8143 development. Issued 5.7 million common shares, 2.5 million pre-funded warrants, and 4.1 million Series E warrants. Outstanding warrants represent potential dilution equal to 72% of current common stock.
9 days ago
24Sep
Surrozen shares jump 98% on FDA IND filing for eye therapy
Surrozen Inc. shares rose 98.45% to $32.07 following an FDA IND submission. The IND application covers SZN-8141, a dual-mechanism therapy for diabetic macular edema. Preclinical data showed superior efficacy over single-agent treatments in rodent models. Phase 1b/2a trial enrollment is expected to begin by late 2026. Cash and cash equivalents stood at $102.0 million as of June 30.
1mo ago
3Sep
Surrozen to present at Cantor and Morgan Stanley healthcare conferences
Surrozen to hold fireside chats at Cantor and Morgan Stanley healthcare conferences in September 2026. Company plans to initiate DUET Phase 1b/2a study in DME patients by year-end 2026. IND application for SZN-8141 targeted for submission by end of third quarter 2026. Partnership with Boehringer Ingelheim includes potential royalties and milestone payments.
1mo ago
16Jul
Surrozen to present at H.C. Wainwright ophthalmology conference
Surrozen Inc. will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026, with a fireside chat at 10:00 AM Pacific Time. The webcast will be accessible via the company's website, with a replay available for 30 days.
